Immune-Mediated Organ-Specific Reactions to COVID-19 Vaccines: A Retrospective Descriptive Study

被引:2
|
作者
Ruiz-Fernandez, Carmen [1 ]
Cuesta, Ricardo [1 ]
Martin-Lopez, Susana [2 ]
Guijarro, Javier [2 ]
de las Huertas, Arturo Lopez Gomez [2 ]
Urroz, Mikel [2 ]
Miguel-Berenguel, Laura [1 ]
Gonzalez-Munoz, Miguel [1 ]
Ramirez, Elena [2 ]
机构
[1] La Paz Univ Hosp IdiPAZ, Immunol Dept, Madrid 28046, Spain
[2] Univ Autonoma Madrid, La Paz Univ Hosp IdiPAZ, Fac Med, Clin Pharmacol Dept, Madrid 28046, Spain
关键词
COVID-19; vaccines; adverse drug reactions; delayed hypersensitivity reactions; causality algorithms; lymphocyte transformation test; POLYETHYLENE-GLYCOLS; CAUSALITY ASSESSMENT; HYPERSENSITIVITY; ALLERGY;
D O I
10.3390/ph16050720
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Severe acute respiratory syndrome coronavirus 2 caused the global COVID-19 pandemic and public health crisis, and it led to the rapid development of COVID-19 vaccines, which can cause rare and typically mild hypersensitivity reactions (HRs). Delayed HRs to COVID-19 vaccines have been reported, and the excipients polyethylene glycol (PEG)2000 and polysorbate 80 (P80) are the suspected culprits. Skin patch tests do not help in diagnosing delayed reactions. We aimed to perform lymphocyte transformation tests (LTT) with PEG2000 and P80 in 23 patients with suspected delayed HRs. Neurological reactions (n = 10) and myopericarditis reactions (n = 6) were the most frequent complications. Seventy-eight percent (18/23) of the study patients were admitted to a hospital ward, and the median time to discharge was 5.5 (IQR, 3-8) days. Some 73.9% of the patients returned to baseline condition after 25 (IQR, 3-80) days. LTT was positive in 8/23 patients (5/10 neurological reactions, 2/4 hepatitis reactions and 1/2 rheumatologic reactions). All myopericarditis cases had a negative LTT. These preliminary results indicate that LTT with PEGs and polysorbates is a useful tool for identifying excipients as causal agents in HRs to COVID-19 vaccines and can play an important role in risk stratification in patients with HRs.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Organ-specific or personalized treatment for COVID-19: rationale, evidence, and potential candidates
    Mousavi, Seyedeh Zahra
    Rahmanian, Mojdeh
    Sami, Ashkan
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2022, 22 (03) : 429 - 433
  • [42] Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
    Torres, Tiago
    Puig, Luis
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (03) : 307 - 311
  • [43] COVID-19: a potential driver of immune-mediated breast cancer recurrence?
    Francescangeli, Federica
    De Angelis, Maria Laura
    Zeuner, Ann
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [44] In situ immune-mediated pulmonary artery thrombosis and Covid-19 pneumonitis
    Mandal, Amit K. J.
    Kho, Jason
    Ioannou, Adam
    Van den Abbeele, Koenraad
    Missouris, Constantinos G.
    THROMBOSIS RESEARCH, 2021, 197 : 112 - 113
  • [45] Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism
    Gouse, Brittany M.
    Spears, William E.
    Archibald, Ashley Nieves
    Montalvo, Cristina
    BRAIN BEHAVIOR AND IMMUNITY, 2020, 89 : 529 - 530
  • [46] COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease
    Wen Yanfang
    Chen Jianfeng
    Liu Changlian
    Wang Yan
    Advances in Rheumatology, 63
  • [47] COVID-19: a potential driver of immune-mediated breast cancer recurrence?
    Federica Francescangeli
    Maria Laura De Angelis
    Ann Zeuner
    Breast Cancer Research, 22
  • [48] COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases
    Serra Lopez-Matencio, Jose M.
    Vicente-Rabaneda, Esther F.
    Alanon, Estefania
    Aranguren Oyarzabal, Ainhoa
    Martinez Fleta, Pedro
    Castaneda, Santos
    Maggi, Fabrizio
    Bordi, Licia
    VACCINES, 2023, 11 (12)
  • [49] COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease
    Yanfang, Wen
    Jianfeng, Chen
    Changlian, Liu
    Yan, Wang
    ADVANCES IN RHEUMATOLOGY, 2023, 63 (01)
  • [50] COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases
    Gauckler, Philipp
    Kesenheimer, Jana S.
    Geetha, Duvuru
    Odler, Balazs
    Eller, Kathrin
    Laboux, Timothee
    Alberici, Federico
    Zappa, Mattia
    Chebotareva, Natasha
    Moiseev, Sergey
    Bonilla, Marco
    Jhaveri, Kenar D.
    Oniszczuk, Julie
    Audard, Vincent
    Costa, Denise
    Mastroianni-Kirsztajn, Gianna
    Bruchfeld, Annette
    Muto, Masahiro
    Windpessl, Martin
    Mayer, Gert
    Kronbichler, Andreas
    FRONTIERS IN IMMUNOLOGY, 2023, 14